Mumbai, November 2025: Brokerage firm Systematix Institutional Research has maintained its ‘Buy’ rating on Orchid Pharma, even after the company reported a sharp decline in earnings for the second quarter of FY26. The report noted that the slump in profits was largely due to temporary operational challenges and higher input costs, which are expected to ease in the coming quarters.
Systematix analysts believe Orchid Pharma’s strong product pipeline, API capabilities, and expanding export markets will drive medium-term recovery. The firm highlighted that the company’s fundamentals remain solid, with improving margins and robust demand for key antibiotic products. Despite short-term volatility, Systematix continues to project a positive long-term outlook, reaffirming confidence in Orchid Pharma’s growth trajectory.
Leave a Reply